iTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Update

iTeos Therapeutics, Inc. (NASDAQ:ITOS) was the target of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 1,410,000 shares, a growth of 5.2% from the January 15th total of 1,340,000 shares. Approximately 4.6% of the shares of the stock are sold short. Based on an average trading volume of 419,500 shares, the short-interest ratio is presently 3.4 days.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ITOS shares. HC Wainwright reiterated a “buy” rating and issued a $21.00 price target on shares of iTeos Therapeutics in a research report on Thursday, January 16th. Wedbush reiterated an “outperform” rating and issued a $25.00 price target on shares of iTeos Therapeutics in a research report on Friday, January 10th. Finally, Wells Fargo & Company reduced their price target on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a research report on Thursday, December 19th.

iTeos Therapeutics Price Performance

Shares of iTeos Therapeutics stock traded up $0.13 on Monday, hitting $7.40. 167,573 shares of the company’s stock traded hands, compared to its average volume of 250,342. iTeos Therapeutics has a one year low of $7.06 and a one year high of $18.75. The company has a fifty day moving average of $7.66 and a two-hundred day moving average of $10.27. The company has a market capitalization of $270.32 million, a price-to-earnings ratio of -2.35 and a beta of 1.38.

Insider Buying and Selling

In other news, CFO Matthew Gall acquired 5,000 shares of iTeos Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The shares were acquired at an average price of $7.73 per share, for a total transaction of $38,650.00. Following the transaction, the chief financial officer now directly owns 65,429 shares of the company’s stock, valued at approximately $505,766.17. The trade was a 8.27 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 12.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On iTeos Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. nVerses Capital LLC raised its stake in iTeos Therapeutics by 212.5% during the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after buying an additional 1,700 shares during the period. Point72 DIFC Ltd acquired a new position in iTeos Therapeutics during the 3rd quarter worth approximately $31,000. Virtus ETF Advisers LLC raised its stake in iTeos Therapeutics by 58.2% during the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock worth $69,000 after buying an additional 3,293 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in iTeos Therapeutics by 60.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after buying an additional 2,646 shares during the period. Finally, Forefront Analytics LLC acquired a new position in iTeos Therapeutics during the 4th quarter worth approximately $85,000. Institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.